Jeff Michalski
Overview
Explore the profile of Jeff Michalski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
109
Citations
4328
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Spratt D, Liu V, Michalski J, Davicioni E, Berlin A, Simko J, et al.
Int J Radiat Oncol Biol Phys
. 2024 Sep;
120(5):1461.
PMID: 39320298
No abstract available.
2.
Flaig T, Spiess P, Abern M, Agarwal N, Bangs R, Buyyounouski M, et al.
J Natl Compr Canc Netw
. 2024 May;
22(4):216-225.
PMID: 38754471
Bladder cancer, the sixth most common cancer in the United States, is most commonly of the urothelial carcinoma histologic subtype. The clinical spectrum of bladder cancer is divided into 3...
3.
Tward J, Lenz L, Gutin A, Clegg W, Kasten C, Finch R, et al.
JCO Precis Oncol
. 2024 May;
8:e2300722.
PMID: 38748970
Purpose: Guidelines recommend adding androgen-deprivation therapy (ADT) to radiation therapy (RT) in certain patients with localized prostate cancer. Individualized genomic testing may improve the prognostic accuracy of risk assessments. Herein,...
4.
ACR-ACNM-ARS-ASTRO-SNMMI Practice Parameter for the Performance of Therapy With Radiopharmaceuticals
Wallner P, Yoo D, Calais J, Escorcia F, Mari Aparici C, Michalski J, et al.
Am J Clin Oncol
. 2023 Dec;
47(4):169-176.
PMID: 38131352
Objectives: This practice parameter was revised collaboratively by the American College of Radiology (ACR), the American College of Nuclear Medicine, the American Radium Society, the American Society for Radiation Oncology,...
5.
Benabdallah N, Lu P, Abou D, Zhang H, Ulmert D, Hobbs R, et al.
J Nucl Med
. 2023 Dec;
65(2):245-251.
PMID: 38124163
α-particle emitters are emerging as a potent modality for disseminated cancer therapy because of their high linear energy transfer and localized absorbed dose profile. Despite great interest and pharmaceutical development,...
6.
Waters M, Price A, Laugeman E, Henke L, Hugo G, Stowe H, et al.
Clin Transl Radiat Oncol
. 2023 Nov;
44:100693.
PMID: 38021093
Introduction: Stereotactic body radiation therapy (SBRT) is an emerging treatment modality for clinically localized prostate cancer (PCa). Online daily adaptive radiotherapy (ART) could potentially improve the therapeutic ratio of prostate...
7.
Fitzgerald T, Bishop-Jodoin M, Laurie F, Iandoli M, Smith K, Ulin K, et al.
Semin Radiat Oncol
. 2023 Sep;
33(4):395-406.
PMID: 37684069
Clinical trials have been the center of progress in modern medicine. In oncology, we are fortunate to have a structure in place through the National Clinical Trials Network (NCTN). The...
8.
Ganeshan D, Khatri G, Ali N, Avery R, Caserta M, Chang S, et al.
J Am Coll Radiol
. 2023 May;
20(5S):S246-S264.
PMID: 37236747
Renal cell carcinoma is a complex group of highly heterogenous renal tumors demonstrating variable biological behavior. Pretreatment imaging of renal cell carcinoma involves accurate assessment of the primary tumor, presence...
9.
Spratt D, Liu V, Michalski J, Davicioni E, Berlin A, Simko J, et al.
Int J Radiat Oncol Biol Phys
. 2023 May;
117(2):370-377.
PMID: 37137444
Purpose: Intermediate-risk prostate cancer is a heterogeneous disease state with diverse treatment options. The 22-gene Decipher genomic classifier (GC) retrospectively has shown to improve risk stratification in these patients. We...
10.
Kavuma A, Kibudde S, Schmidt M, Zhao T, Gay H, Li B, et al.
Adv Radiat Oncol
. 2023 Feb;
8(3):101180.
PMID: 36846439
Purpose: There is a vital need to train radiation therapy professionals in low- and middle-income countries (LMICs) to develop sustainable cancer treatment capacity and infrastructure. LMICs have started to introduce...